Protagonist Therapeutics (PTGX) Accounts Payables (2017 - 2025)
Historic Accounts Payables for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $22.9 million.
- Protagonist Therapeutics' Accounts Payables rose 1026.57% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 1026.57%. This contributed to the annual value of $23.7 million for FY2024, which is 2239.38% up from last year.
- Protagonist Therapeutics' Accounts Payables amounted to $22.9 million in Q3 2025, which was up 1026.57% from $15.4 million recorded in Q2 2025.
- Protagonist Therapeutics' 5-year Accounts Payables high stood at $37.7 million for Q4 2021, and its period low was $11.8 million during Q1 2025.
- Its 5-year average for Accounts Payables is $23.1 million, with a median of $20.7 million in 2024.
- Per our database at Business Quant, Protagonist Therapeutics' Accounts Payables soared by 11304.94% in 2021 and then tumbled by 4954.37% in 2023.
- Protagonist Therapeutics' Accounts Payables (Quarter) stood at $37.7 million in 2021, then crashed by 33.83% to $25.0 million in 2022, then decreased by 22.43% to $19.4 million in 2023, then increased by 22.39% to $23.7 million in 2024, then fell by 3.48% to $22.9 million in 2025.
- Its Accounts Payables was $22.9 million in Q3 2025, compared to $15.4 million in Q2 2025 and $11.8 million in Q1 2025.